Date: 2013-09-26
Type of information: Development agreement
Compound: PP-001
Company: 4SC (Germany) Panoptes Pharma (Austria)
Therapeutic area: Ophtalmological diseases
Type agreement: development
Action mechanism: PP-001 is a highly specific immunomodulating small molecule targeting the molecular causes of uveitis and adenoviral conjunctivitis. Efficacy of PP-001 has been established in animal models for uveitis and viral indications.
Disease: uveitis, viral conjunctivitis
Details: * On September 26, 2013, 4SC, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, has announced that its wholly-owned research subsidiary 4SC Discovery has entered into a patent transfer agreement with Austrian biotechnology company Panoptes Pharma. The agreement gives Panoptes Pharma full patent rights to an anti-inflammatory, small molecule substance that was discovered by 4SC Discovery and is currently in preclinical development stage. Panoptes will continue developing this substance - the immune modulator PP-001 - for therapeutic application in the field of inflammatory eye diseases with high medical need and will market the compound if development is successful. Target indications of Panoptes for the substance are uveitis and viral conjunctivitis (commonly known as \'pink eye\').
In return, 4SC Discovery receives a share of 24.9% in Panoptes Pharma and is entitled to subsequent, performance-based milestone payments and royalties based on the sales revenue generated with the compound. Furthermore, 4SC Discovery has the right to use the compound in the therapeutic fields of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). In the event of the further development and/or commercialisation of the compound in RA and/or IBD by 4SC Discovery, Panoptes would be entitled to milestone payments and royalties.
Financial terms:
Latest news:
